Athira Pharma, Inc. (ATHA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Loading interactive chart…
- GlobeNewswire
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025 Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore
- Zacks
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
- Barrons.com
Alzheimer’s Trial Failure Sends Athira Stock Down 75%
Athira’s experimental drug fosgonimeton failed to slow cognitive decline. The biotech firm says it’s not giving up.
© 2024 Yahoo. All rights reserved.